Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 2133)
eröffnet am 25.04.09 09:22:26 von
neuester Beitrag 11.05.24 22:58:55 von
neuester Beitrag 11.05.24 22:58:55 von
Beiträge: 22.997
ID: 1.149.910
ID: 1.149.910
Aufrufe heute: 98
Gesamt: 1.241.396
Gesamt: 1.241.396
Aktive User: 0
ISIN: US6700024010 · WKN: A2PKMZ · Symbol: NVAX
8,2570
EUR
+96,67 %
+4,0585 EUR
Letzter Kurs 10.05.24 Tradegate
Neuigkeiten
10.05.24 · wallstreetONLINE Redaktion |
10.05.24 · dpa-AFX |
10.05.24 · dpa-AFX |
10.05.24 · dpa-AFX |
Wendepunkt für die Aktie?: Novavax: Multimilliarden-Dollar-Deal mit Sanofi – Aktie verdoppelt sich!Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 8,8800 | +57,45 | |
| 17,440 | +44,61 | |
| 1,9750 | +27,42 | |
| 1,8400 | +26,03 | |
| 4,9500 | +25,32 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,965 | -18,48 | |
| 0,7845 | -19,36 | |
| 3,3200 | -22,61 | |
| 0,6785 | -26,19 | |
| 3,3100 | -77,44 |
Beitrag zu dieser Diskussion schreiben
Feedback
Ich denke, dass für Polen und andere EU Länder der Impfstoff von Novavax kommen wird. Die letzten werden die ersten sein (Novavax mit neuem Impfstoff, Sputnik - neuer Imofstoff! von den Russen, Algernon mit seinem neuen Cornamedikament, usw).
Antwort auf Beitrag Nr.: 66.951.620 von DasTier666 am 11.02.21 12:51:08
Das Zeitfenster schließt sich bald. Ich gespannt, ob da noch was kommt
Zitat von DasTier666: EU close to sealing supply deal with Novavax for COVID-19 vaccines
FEBRUARY 11, 2021 11:11 AM
BRUSSELS (Reuters) - The European Union could sign a supply deal with Novavax this week or next for the U.S. company’s COVID-19 vaccine candidate, two EU officials involved in the talks with the firm said.
The EU concluded in December preliminary negotiations with Novavax for the supply of 100 million doses and an option for another 100 million.
“Talks with Novavax have intensified and we aim to agree the contract this week or next,” one EU official said.
https://www.reuters.com/article/idUSL1N2KH0Q1
Das Zeitfenster schließt sich bald. Ich gespannt, ob da noch was kommt
Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine
Feb 18, 2021 at 4:02 PM EST
- Advances joint commitment from Novavax, Serum Institute of India and Gavi to ensure equitable access to NVX-CoV2373 worldwide across low-, middle- and high-income countries
-Memorandum of understanding (MOU) between Gavi and Novavax to make available a cumulative volume of 1.1 billion doses of the Novavax vaccine to the COVAX Facility
https://ir.novavax.com/news-releases/news-release-details/no…
Feb 18, 2021 at 4:02 PM EST
- Advances joint commitment from Novavax, Serum Institute of India and Gavi to ensure equitable access to NVX-CoV2373 worldwide across low-, middle- and high-income countries
-Memorandum of understanding (MOU) between Gavi and Novavax to make available a cumulative volume of 1.1 billion doses of the Novavax vaccine to the COVAX Facility
https://ir.novavax.com/news-releases/news-release-details/no…
Die Einschreibung für die US Studie scheint beendet worden zu sein
"This trial has completed recruitment on this platform, and is no longer accepting new referrals."
https://www.novavax.com/PREVENT-19?utm_source=nvax&utm_mediu…
"This trial has completed recruitment on this platform, and is no longer accepting new referrals."
https://www.novavax.com/PREVENT-19?utm_source=nvax&utm_mediu…
EU close to sealing supply deal with Novavax for COVID-19 vaccines
FEBRUARY 11, 2021 11:11 AM
BRUSSELS (Reuters) - The European Union could sign a supply deal with Novavax this week or next for the U.S. company’s COVID-19 vaccine candidate, two EU officials involved in the talks with the firm said.
The EU concluded in December preliminary negotiations with Novavax for the supply of 100 million doses and an option for another 100 million.
“Talks with Novavax have intensified and we aim to agree the contract this week or next,” one EU official said.
https://www.reuters.com/article/idUSL1N2KH0Q1
FEBRUARY 11, 2021 11:11 AM
BRUSSELS (Reuters) - The European Union could sign a supply deal with Novavax this week or next for the U.S. company’s COVID-19 vaccine candidate, two EU officials involved in the talks with the firm said.
The EU concluded in December preliminary negotiations with Novavax for the supply of 100 million doses and an option for another 100 million.
“Talks with Novavax have intensified and we aim to agree the contract this week or next,” one EU official said.
https://www.reuters.com/article/idUSL1N2KH0Q1
Trading Spotlight
Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization
Feb 04, 2021 at 4:05 PM EST
GAITHERSBURG, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the start of the rolling review process for authorization of NVX-CoV2373, its COVID-19 vaccine, by multiple regulatory agencies. The reviews will continue while the company completes its pivotal Phase 3 trials in the United Kingdom (U.K.) and United States (U.S.) and through initial authorization for emergency use granted under country-specific regulations.
“The rolling review of our submission by regulatory authorities of non-clinical data and early clinical studies will help expedite the review process and bring us that much closer to delivering a safe and effective vaccine worldwide,” said Gregory M. Glenn, MD, President of Research and Development, Novavax. “We appreciate the agencies’ confidence in Novavax based on our early data and the collective sense of urgency to ensure speedier access to much-needed COVID-19 vaccination.”
To date, Novavax has begun the rolling review process with several regulatory agencies worldwide, including the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), U.K. Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada. As part of the rolling review, the company will continue to submit additional information, including clinical and manufacturing data.
Novavax’ recombinant protein-based vaccine candidate is currently in Phase 3 clinical development in both the U.K. and U.S. for the prevention of COVID-19. It was the first vaccine to demonstrate clinical efficacy against the original strain of COVID-19 and both of the rapidly emerging variants in the United Kingdom and South Africa.
https://ir.novavax.com/news-releases/news-release-details/no…
Feb 04, 2021 at 4:05 PM EST
GAITHERSBURG, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the start of the rolling review process for authorization of NVX-CoV2373, its COVID-19 vaccine, by multiple regulatory agencies. The reviews will continue while the company completes its pivotal Phase 3 trials in the United Kingdom (U.K.) and United States (U.S.) and through initial authorization for emergency use granted under country-specific regulations.
“The rolling review of our submission by regulatory authorities of non-clinical data and early clinical studies will help expedite the review process and bring us that much closer to delivering a safe and effective vaccine worldwide,” said Gregory M. Glenn, MD, President of Research and Development, Novavax. “We appreciate the agencies’ confidence in Novavax based on our early data and the collective sense of urgency to ensure speedier access to much-needed COVID-19 vaccination.”
To date, Novavax has begun the rolling review process with several regulatory agencies worldwide, including the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), U.K. Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada. As part of the rolling review, the company will continue to submit additional information, including clinical and manufacturing data.
Novavax’ recombinant protein-based vaccine candidate is currently in Phase 3 clinical development in both the U.K. and U.S. for the prevention of COVID-19. It was the first vaccine to demonstrate clinical efficacy against the original strain of COVID-19 and both of the rapidly emerging variants in the United Kingdom and South Africa.
https://ir.novavax.com/news-releases/news-release-details/no…
Poland to have two new vaccine suppliers from 2nd quarter
FEBRUARY 01, 2021
Poland plans to sign contracts with two new vaccines suppliers, Novavax and Johnson&Johnson, in the second quarter of this year, the health minister said on Monday.
...
"In the second quarter we are expecting at least one decision concerning the Novavax company, and another on Johnson&Johnson,” Niedzielski said. “This means two more suppliers."
...
https://www.thefirstnews.com/article/poland-to-have-two-new-…
FEBRUARY 01, 2021
Poland plans to sign contracts with two new vaccines suppliers, Novavax and Johnson&Johnson, in the second quarter of this year, the health minister said on Monday.
...
"In the second quarter we are expecting at least one decision concerning the Novavax company, and another on Johnson&Johnson,” Niedzielski said. “This means two more suppliers."
...
https://www.thefirstnews.com/article/poland-to-have-two-new-…
Antwort auf Beitrag Nr.: 66.824.152 von DasTier666 am 04.02.21 18:11:14Auch wenn mir diese Aktie hier viele graue Haare eingebracht hat.
Das kann ich mit dir teilen. Ich hatte auch hohe Verluste mit dieser Aktie. Erst zu teuer gekauft, dann stürzte sie auch noch heftig ab. Aber grundsätzlich schöne Gewinne eingefahren.
Ich überlege noch ein bisschen. Danke für deine ausführlichen Zeilen.gruss mfierke
Das kann ich mit dir teilen. Ich hatte auch hohe Verluste mit dieser Aktie. Erst zu teuer gekauft, dann stürzte sie auch noch heftig ab. Aber grundsätzlich schöne Gewinne eingefahren.
Ich überlege noch ein bisschen. Danke für deine ausführlichen Zeilen.gruss mfierke
Antwort auf Beitrag Nr.: 66.823.549 von mfierke am 04.02.21 17:45:06Das ist schwierig, so eine Frage zu beantworten. Aber ich finde realisierte Gewinne immer gut, auch wenn es hätte mehr sein können.
Meiner Meinung nach ist aber auf lange Sicht noch einiges drin. In Aussicht steht ja die Genehmigung für Kanada, UK, Japan und die EU. Dann kommen die Ergebnisse der US Phase III. Hinzu kommt hoffentlich noch dieses Jahr die Einreichung der BLA für NanoFlu und der Ausblick für RSV. Dann haben wir noch die Malaria Phase II mit dem Serum Institute of India.
Es ist halt viel Konjunktiv, aber das ist der Reiz der Börse. Auch wenn mir diese Aktie hier viele graue Haare eingebracht hat.
Meiner Meinung nach ist aber auf lange Sicht noch einiges drin. In Aussicht steht ja die Genehmigung für Kanada, UK, Japan und die EU. Dann kommen die Ergebnisse der US Phase III. Hinzu kommt hoffentlich noch dieses Jahr die Einreichung der BLA für NanoFlu und der Ausblick für RSV. Dann haben wir noch die Malaria Phase II mit dem Serum Institute of India.
Es ist halt viel Konjunktiv, aber das ist der Reiz der Börse. Auch wenn mir diese Aktie hier viele graue Haare eingebracht hat.
Antwort auf Beitrag Nr.: 66.823.222 von DasTier666 am 04.02.21 17:31:23Kann man bei den kurs noch einsteigen? Ich bin man glabt es nicht,bei 152 euro ausgestiegen.seit dem suche ich den einstieg und finde ihn nicht. DUMMHEIT MUß BESTRAT WERDEN
Durchsuchen
Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage
